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The in vitro permeability of valsartan through excised rat skin was investigated using Franz-type 
diffusion cells. The permeation was assessed by studying the effect of water, polysorbate-80 and 
eucalyptus oil on the permeability flux of valsartan through excised rat skin. The slope of linear portion 
of the graph obtained by plotting the cumulative amount of valsartan permeated per unit skin surface 
area as a function of time provided the permeability flux. Of the vehicles studied, only 6.0 % w/v 
polysorbate-80 solution provided most permeation of valsartan through the rat skin as evidenced by the 
highest permeability coefficient of valsartan. 
 




The in vitro study of skin permeability plays an 
essential role in the selection of candidates for the 
development of transdermal dosage forms. Human 
skin either excised from surgical reduction or 
obtained from a cadaver is the membrane of choice. 
However, due to ethical considerations human skin 
is often being substituted with animal skin such as 
hairless rat, rabbit, pig and shed snake as a model 
membrane (Brisset and McBride, 1983; Priborsky et 
al., 1987). Transdermal drug delivery avoids 
problems associated with gastrointestinal 
intolerance, reduces first-pass liver metabolism, 
increases drug efficacy and is applicable to drugs 
with short half-lives (Bhatia et al., 1997)  Due to the 
highly organized structure of the stratum corneum 
that forms an effective barrier to the permeation of 
drugs through the skin, a number of dermal 
permeation enhancing methods have been 
investigated in order to overcome the barrier 
property of the stratum corneum .Dermal 
permeation enhancement by chemical enhancers is 
one of those methods and chemical substances 
studied  include water (Warster and Kramer, 1961), 
sulphoxides (Stoughton and Fritsch, 1964), 
propylene glycol (Toniton, 1986), azones 
(Watkinson, 1991), alcohols and acids (Doshi and 
Chien, 1989), esters (Catz and Heller, 1989), 
surfactants (Hwang and Danti, 1983) and essential 
oils (Monti et al., 2002). Valsartan, N-[p-(o-1H-
tetrazol-5-ylphenyl)benzyl]-N-valeryl-L-valine is a 
potent long-acting non-peptide angiotensin II-
receptor antagonist with high specificity for AT1 
subtype (Latif et al., 2001). It is used clinically to 
treat hypertension. Although valsartan is rapidly 
absorbed following oral administration, has 
moderate bioavailability and biological half-life 
(Flesch et al., 1997), it is considered a good 
candidate for transdermal drug delivery because of 
relative high inter and intra-patient variability 
associated with the only available dosage form of 
the drug. Also it will serve to provide an alternative 
dosage form of the drug that could benefit geriatric 
hypertensive patients. To explore the possibility of 
developing a transdermal therapeutic system for 
valsartan, we studied the effect of water, 
polysorbate-80 and eucalyptus oil on the 
permeability of valsartan through excised rat skin. 
Polysorbate-80 was chosen because the solubility 
of valsartan (a poorly water soluble drug) has been 
reported to be significantly increased by the 
aqueous solutions of the surfactant (Mbah, 2006). 
Furthermore, nonionic surfactants and essential oils 
have also been reported to be dermal absorption 
enhancers. To our knowledge, there is little or no 
study on percutaneous absorption of valsartan, and 
in this paper, the effect of these vehicles on the 
permeation of valsartan through excised rat skin 
was investigated.  
 
Materials and Methods 
 
Valsartan (Norvatis Pharmaceuticals, USA), 
eucalyptus oil (Sanoflore, France) and all other 
solvents were of analytical grade (BDH). 
Ultraviolet/Visible spectrophotometer (UV 2102 PC 
Unico). 
 
Standard solution: Stock solution of valsartan (20 
µg/ml) was prepared in methanol. Aliquots of the 
standard stock solution were pipetted into a 10 ml 
volumetric flask and diluted to volume with 
methanol to give the final concentration of 2-10 
µg/ml of valsartan. 
 
Preparation of rat abdominal skin: The male 
albino rats (140-200 g) used for the preparation of 
the skin was obtained from the Faculty of Veterinary 
Medicine, University of Nigeria, Nsukka. They were 
allowed free access to food and water until used for 
the study. The rats were euthaniased using 
carbondioxide asphyxiation. The dorsal hair was 
removed with a clipper and full thickness skin was 
surgically removed from each rat. The entire 
abdominal skin was soaked in water at 60 º C for 
about 1 min, followed by careful removal of the 
epidermis (Shen et al., 1976). The epidermis was 
washed with water and used in the in vitro 
permeability studies. The skin samples were stored 
at –18 º C and placed at 4 º C the day before the 
study.  
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Table 1:  Valsartan skin permeation parameters from polysorbate-80 solution using Franz cells 
Permeation Parameters Polysorbate-80 
solution   (% w/v) Flux  (µg/cm2/h) Kp   (cm/h x 103) Dapp    (cm2/h) K 
ER 
0.0 8.31 + 0.164 1.66 + 0.082 3.14 x 10¯3 29.6 1.00 
0.5 3.91 + 0.024 0.79 + 0.054 3.14 x 10¯3 14.1 0.48 
1.0 6.37 + 0.073 1.27 + 0.060 3.14 x 10¯3 22.7 0.72 
2.0 8.68 + 0.097 1.74 + 0.031 3.14 x 10¯3 31.0 1.05 
4.0 10.46 + 0.150 2.09 + 0.090 3.14 x 10¯3 37.3 1.26 
6.0 11.07 + 0.118 2.21 + 0.046 3.14 x 10¯3 37.4 1.33 
 
Table 2: Valsartan skin permeation parameters from emulsion formulation in 1.0 % (w/v) micellar solution 
using Franz cells 
Permeation Parameters Emulsion  (% v/v) 
 Flux  (µg/cm2/h) Kp   (cm/h x 103) Dapp    (cm2/h) K 
ER 
1.0 1.62 + 0.017 0.32 + 0.029 3.14 x 10¯3 5.7 0.19 
5.0 3.52 + 0.033 0.70 + 0.015 3.14 x 10¯3 12.4 0.42 
10.0 5.66 + 0.049 1.13 + 0.029 3.14 x 10¯3 20.15 0.68 
 
Table 3:   Valsartan skin permeation parameters from emulsion formulation in 2.0 % (w/v) polysorbate-80 
solution using Franz cells 
Permeation Parameters Emulsion  (% 
v/v) Flux  (µg/cm2/h) Kp   (cm/h x 103) Dapp    (cm2/h) K 
ER 
    1.0 2.09 + 0.086 0.420 + 0.012 3.14 x 10¯3 7.49 0.25 
    5.0 5.36 + 0.131 1.07 + 0.037 3.14 x 10¯3 19.08 0.64 





























Two hours before the beginning of the experiment, 
the skin was preequilibrated in phosphate buffer 
solution at 25 º C. 
 
In vitro skin permeability studies: The Franz 
diffusion cells were used in the in vitro permeation 
studies. A circular specimen of the skin was 
sandwiched securely between the compartments of 
the diffusion cell with the stratum corneum facing 
the donor compartment. The effective diffusional 
area was 2.27cm2 . The receiver compartment (25 
ml) was filled with ethanol and water in the ratio of 
70 : 30 % v/v in order to maintain sink conditions. 
The drug solution (5 mg/ml) in various vehicles was 
added to the donor compartment. The cells were 
maintained at 37 + 1 º C by a magnetic stirrer with 
heater and the contents in the receiver cell were 
magnetically stirred. At appropriate intervals (1, 2, 
4, 6, 8, 12, and 24 h) 2 ml samples were withdrawn 
from the receiver cell and replaced with an 
equivalent quantity of drug free solvent (70 : 30 % 
v/v ethanol-water) to maintain a constant volume. 
The samples were analyzed by spectrophotometry 
at a maximum wavelength of 260 nm and the 
valsartan content obtained from pre-constructed 
calibration graph.   
Fig.1: Plot of cumulative amount of
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Permeation data analysis and statistics: The 
steady-state flux (µg/cm2/h) was calculated using 
linear regression analysis by plotting cumulative 
amount of valsartan permeated through the rat skin 
as a function of time and dividing a slope of the 
linear portion of the plot by the area of the skin 
surface through which diffusion occurred (Julreht et 
al., 1998).  
The lag time (tl) was calculated from the x-
intercept values of the regression lines The 
permeability coefficient (Kp) was calculated by 
dividing the flux value at steady-state by the donor 
cell initial concentration of valsartan.  
The apparent diffusion coefficient (Dapp) 
was estimated from the lag time values according to 
the following equation (Flynn et al., 1974) : Dapp = h2 
/ tl , where h is the barrier (skin) thickness, tl is the 
lag time. 
The stratum corneum / vehicle partition 
coefficient (K) can be calculated from the following 
equation (Montenegro et al., 2007): K = Kp h / Dapp,
The penetration enhancing effect of the 
vehicle was calculated in terms of enhancement 
ratio (ER) using the following equation (Williams  
 







































and Barry, 1994): ER = Kp with vehicle / Kp with 
water. 
Statistical comparisons were made using 
the student’s t-test. A value of p < 0.05 was 
considered statistically significant. 
 
Results and Discussion 
 
The in vitro skin permeation of valsartan was 
evaluated using the finite dose technique. The 
percutaneous absorption parameters obtained from 
water and polysorbate-80 solutions using Franz 
diffusion cells are listed in Table1. The skin 
permeation rates of valsartan were found to 
increase with increase in the concentration of the 
micellar solution. For example, the permeability flux 
(Table 1) of valsartan from 0.5 %, 1.0 %, 2.0 %, 4.0 
% and 6.0 % w/v micellar solution was 3.91+ 0.02 
µg/cm2/h, 6.37 + 0.07 µg/cm2/h, 8.68 + 0.10 
µg/cm2/h, 10.46 + 0.15 µg/cm2/h, 11.07 + 0.12 
µg/cm2 respectively. The results also show the 
permeability flux of the drug from water to be 8.31 + 
0.16 µg/cm2/h. The lag period for permeation of 
valsartan through the excised rat skin from micellar 
solutions and water respectively was found to be 
about 1h. The skin permeation profile of valsartan 
from water and polysorbate-80 solution is shown in 
Fig. 1.The effect of eucalyptus oil on the permeation 
rates of valsartan was studied by introducing 
varying volumes of oil into 1.0 % w/v and 2.0 % w/v 
polysorbate-80 solutions respectively. The results 
are given in Tables 2 and 3 respectively. It was 
found that the permeation rates of valsartan from 
the emulsions formed using 2.0 %w/v polysorbate-
80 solution were higher than that obtained with 1.0 
% w/v polysorbate-80 solution. For instance, the 
permeability flux (Table 2) of valsartan from 1.0 %, 
5.0 % and 10.0 % v/v emulsion formed using 
eucalyptus oil and 1% w/v polysorbate-80 solution 
was 1.62+ 0.02 µg/cm2/h, 3.52 + 0.03 µg/cm2/h and 
5.66 + 0.05 µg/cm2/h respectively while the 
permeability flux (Table 3) of the drug at the same 
concentration of the emulsion with 2.0 % w/v 
polysorbate-80 solution was 2.09 + 0.09 µg/cm2/h, 
5.36 + 0.13 µg/cm2/h and 6.70 + 0.09 µg/cm2/h 
respectively. The lag period for permeation of 
valsartan through the excised rat skin from the 
emulsions was noted to be about 1h. The skin 
permeation profile of valsartan from the emulsion 
formulations is shown in Fig. 2. The variability 
observed in the permeability flux values for the 
studied vehicles could be attributed to varying 
influences of the vehicles on the biophysical 
properties of the stratum corneum and differences 
in thermodynamic activity of the drug in the 
vehicles.. The biophysical properties of the treated 
stratum corneum with the vehicles were not studied 
to determine the probable mechanism of action. 
However, previous study has shown disruption of 
the lipid bilayers to be the probably mechanism of 
action for surfactants and emulsion formulations 
respectively (Shakeel et al., 2008).  
Fig. 2: Plot of cumulative amount of valsartan












Conclusion: The effect of vehicles on the 
permeation of valsartan through excised rat skin 
using Franz-type diffusion cells in order to select a 
suitable vehicle in the development of a transdermal 
therapeutic system for valsartan was investigated. 
Of the vehicles studied, only 6 % w/v polysorbate-
80 solution showed some degree of dermal 
permeation enhancing properties though insufficient 
to provide any potential use of it as vehicle in 
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